only approximately half of patients with potentially curative resections receive adjuvant therapy due to issues associated with postoperative complications, recovery, and performance status. 9 Median survival for patients with resected tumors under
Search Results
NCCN Guidelines Insights: Pancreatic Adenocarcinoma, Version 1.2019
Featured Updates to the NCCN Guidelines
Margaret A. Tempero, Mokenge P. Malafa, E. Gabriela Chiorean, Brian Czito, Courtney Scaife, Amol K. Narang, Christos Fountzilas, Brian M. Wolpin, Mahmoud Al-Hawary, Horacio Asbun, Stephen W. Behrman, Al B. Benson III, Ellen Binder, Dana B. Cardin, Charles Cha, Vincent Chung, Mary Dillhoff, Efrat Dotan, Cristina R. Ferrone, George Fisher, Jeffrey Hardacre, William G. Hawkins, Andrew H. Ko, Noelle LoConte, Andrew M. Lowy, Cassadie Moravek, Eric K. Nakakura, Eileen M. O’Reilly, Jorge Obando, Sushanth Reddy, Sarah Thayer, Robert A. Wolff, Jennifer L. Burns, and Griselda Zuccarino-Catania
Impact of Axillary Dissection Among Patients With Sentinel Node–Positive Breast Cancer Undergoing Mastectomy
James Sun, Brittany J. Mathias, Christine Laronga, Weihong Sun, Jun-Min Zhou, William J. Fulp, John V. Kiluk, and M. Catherine Lee
without records of adjuvant therapy were excluded. Patients were identified from a prospectively maintained breast cancer database at an NCI-designated Comprehensive Cancer Center. Clinicopathologic variables, including demographic information, pathology
Failure to Undergo Resection Following Neoadjuvant Therapy for Resectable Pancreatic Cancer: A Secondary Analysis of SWOG S1505
Jordan M. Cloyd, Sarah Colby, Katherine A. Guthrie, Andy M. Lowy, E. Gabrielle Chiorean, Phillip Philip, Davendra Sohal, and Syed Ahmad
Background Surgical resection followed by adjuvant therapy has historically been the recommended approach for patients with localized pancreatic ductal adenocarcinoma (PDAC). 1 , 2 Nevertheless, given the challenges in administering adjuvant
NCCN Guidelines® Insights: Non–Small Cell Lung Cancer, Version 2.2023
Featured Updates to the NCCN Guidelines
David S. Ettinger, Douglas E. Wood, Dara L. Aisner, Wallace Akerley, Jessica R. Bauman, Ankit Bharat, Debora S. Bruno, Joe Y. Chang, Lucian R. Chirieac, Malcolm DeCamp, Thomas J. Dilling, Jonathan Dowell, Gregory A. Durm, Scott Gettinger, Travis E. Grotz, Matthew A. Gubens, Aparna Hegde, Rudy P. Lackner, Michael Lanuti, Jules Lin, Billy W. Loo Jr, Christine M. Lovly, Fabien Maldonado, Erminia Massarelli, Daniel Morgensztern, Thomas Ng, Gregory A. Otterson, Sandip P. Patel, Tejas Patil, Patricio M. Polanco, Gregory J. Riely, Jonathan Riess, Steven E. Schild, Theresa A. Shapiro, Aditi P. Singh, James Stevenson, Alda Tam, Tawee Tanvetyanon, Jane Yanagawa, Stephen C. Yang, Edwin Yau, Kristina M. Gregory, and Miranda Hughes
ICIs. Immunotherapy Clinical Trial Data IMpower010, a phase III randomized trial, assessed adjuvant therapy with atezolizumab versus best supportive care in 1,005 patients with completely resected stage IB–IIIA NSCLC (staging
The First Documented Case of High-Grade Synovial Cell Sarcoma of the Rectum
Richard B. Hostetter, Min Yan, Houman Vaghefi, Kenneth Pennington, and Gary Cornette
higher total doses (60–66 Gy in 30–33 fractions). The advantage of adjuvant therapy is that the final pathology is clearly established. 3 Figure 6 Spindle tumor cells in bundle and fascicles (hematoxylin-eosin stain, original magnification x100
Multidisciplinary Management of Pancreatic Cancer
Margaret A. Tempero
pancreatic cancer, 80% of patients are diagnosed with advanced unresectable disease; 80% experience relapse after resection and adjuvant therapy; and median overall survival (OS) of patients with untreated metastatic disease is only 3 months. The “cure rate
Incorporating New Systemic Therapies in Kidney Cancer Treatment
Eric Jonasch
in Oncology (NCCN Guidelines) for Kidney Cancer. Adjuvant Therapy Three trials have been conducted in the adjuvant setting, 2 of which (ASSURE and PROTECT) showed negative results for adjuvant sunitinib, sorafenib, and pazopanib. A third trial
Ten Years of Progress in Colon Cancer Therapy
Paul F. Engstrom
2002, the NCCN panel advocated 5-fluorouracil (5-FU)/leucovorin adjuvant therapy for stage III or node-positive disease and 5-FU leucovorin with or without irinotecan (IFL) as first-line therapy for metastatic disease. Second-line therapies for
Locally Recurrent Endometrial Cancer: A Case Report
Srinivas K. Tantravahi, and Theresa L. Werner
pathologically staged as FIGO stage IA (pT1a pN0 Mx). She received no adjuvant therapy. She returned 3 months later with recurrent vaginal bleeding. A 2-cm friable mass was visualized at the apex of the vaginal cuff on pelvic examination and was resected
Combined Modality Therapy of Localized Gastric and Esophageal Cancers
Prajnan Das, Norio Fukami, and Jaffer A. Ajani
. 29. Gunderson LL Sosin H . Adenocarcinoma of the stomach: areas of failure in a re-operation series (second or symptomatic look) clinicopathologic correlation and implications for adjuvant therapy . Int J Radiat Oncol Biol Phys 1982 ; 8 : 1
